For Immediate Release


Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Subpoena for Ranbaxy’s Toansa Plant

Tokyo, Japan (April, 7, 2014) – Attached is the statement of Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo Company, Limited, which was issued on April 7th, 2014.




Company Statement

April 7th, 2014


United States Attorney’s Office for the District of New Jersey has issued an administrative subpoena dated 13th March to Ranbaxy seeking information primarily related to the Company’s API Toansa manufacturing facility in India for which a Form 483 was issued by FDA culminating into import alert.  The Toansa facility is subject to certain terms of Consent decree entered against Ranbaxy in January 2012. The company is fully cooperating with this information request. Ranbaxy is confident that its pharmaceutical products are safe and effective and is committed in its efforts to remain fully compliant with the US Regulatory standards.